850 related articles for article (PubMed ID: 35346270)
1. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
Regnery S; Ristau J; Weykamp F; Hoegen P; Sprengel SD; Paul KM; Buchele C; Klüter S; Rippke C; Renkamp CK; Pohl M; Meis J; Welzel T; Adeberg S; Koerber SA; Debus J; Hörner-Rieber J
Radiat Oncol; 2022 May; 17(1):102. PubMed ID: 35614486
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric study for spine stereotactic body radiation therapy: magnetic resonance guided linear accelerator versus volumetric modulated arc therapy.
Yadav P; Musunuru HB; Witt JS; Bassetti M; Bayouth J; Baschnagel AM
Radiol Oncol; 2019 Sep; 53(3):362-368. PubMed ID: 31553704
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions.
Bryant JM; Weygand J; Keit E; Cruz-Chamorro R; Sandoval ML; Oraiqat IM; Andreozzi J; Redler G; Latifi K; Feygelman V; Rosenberg SA
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046741
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
7. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.
Henke L; Kashani R; Robinson C; Curcuru A; DeWees T; Bradley J; Green O; Michalski J; Mutic S; Parikh P; Olsen J
Radiother Oncol; 2018 Mar; 126(3):519-526. PubMed ID: 29277446
[TBL] [Abstract][Full Text] [Related]
9. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
10. Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases.
Uder L; Nachbar M; Butzer S; Boldt J; Baumeister S; Bitzer M; Königsrainer A; Seufferlein T; Hoffmann R; Gatidis S; Nikolaou K; Zips D; Thorwarth D; Gani C; Boeke S
Front Oncol; 2022; 12():1095633. PubMed ID: 36727060
[TBL] [Abstract][Full Text] [Related]
11. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers.
Padgett KR; Simpson G; Asher D; Portelance L; Bossart E; Dogan N
Phys Med; 2020 Sep; 77():54-63. PubMed ID: 32781388
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors.
Padgett KR; Simpson GN; Llorente R; Samuels MA; Dogan N
Cureus; 2018 Apr; 10(4):e2423. PubMed ID: 29872603
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
[TBL] [Abstract][Full Text] [Related]
14. Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy.
Rabe M; Palacios MA; van Sörnsen de Koste JR; Eze C; Hillbrand M; Belka C; Landry G; Senan S; Kurz C
Med Phys; 2023 May; 50(5):2625-2636. PubMed ID: 36810708
[TBL] [Abstract][Full Text] [Related]
15. Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis.
Mayinger M; Ludwig R; Christ SM; Dal Bello R; Ryu A; Weitkamp N; Pavic M; Garcia Schüler H; Wilke L; Guckenberger M; Unkelbach J; Tanadini-Lang S; Andratschke N
Radiat Oncol; 2021 May; 16(1):84. PubMed ID: 33947429
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Clinical Results of MR-Guided Stereotactic Body Radiotherapy of Liver Metastases.
Weykamp F; Hoegen P; Regnery S; Katsigiannopulos E; Renkamp CK; Lang K; König L; Sandrini E; Meixner E; Rippke C; Buchele C; Liermann J; Debus J; Klüter S; Hörner-Rieber J
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345123
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes.
Weykamp F; Hoegen P; Klüter S; Spindeldreier CK; König L; Seidensaal K; Regnery S; Liermann J; Rippke C; Koerber SA; Buchele C; Debus J; Hörner-Rieber J
Front Oncol; 2021; 11():610637. PubMed ID: 34178616
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
